Systemic Therapy With Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory Disease

Survey of Ophthalmology

Volumn 56, Issue 6, 2011, Pages 474-510

  Durrani, Khayyam ^a,b,c   Zakka, Fouad R ^a,b,c   Ahmed, Muna ^a,b,c   Memon, Mohiuddin ^a,b,c   Siddique, Sana S ^a,b,c   Foster, C Stephen ^a,b,c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alkylating agents; Antimetabolites; Biologics; Immunomodulatory therapy; Keratitis; Pemphigoid; Scleritis; Uveitis

Indexed keywords

ADALIMUMAB; ALKYLATING AGENT; ALPHA2A INTERFERON; ANTIBIOTIC AGENT; ANTIMETABOLITE; AZATHIOPRINE; CHLORAMBUCIL; CHLORMETHINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DAPSONE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TOCILIZUMAB; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; AGRANULOCYTOSIS; ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; APHASIA; APLASTIC ANEMIA; ASEPTIC MENINGITIS; ATOPIC KERATOCONJUNCTIVITIS; AZOOSPERMIA; BACTERIAL INFECTION; BEHCET DISEASE; BLADDER DISEASE; BLADDER TOXICITY; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BRONCHOSPASM; CHORIORETINOPATHY; CHOROIDITIS; CLINICAL TRIAL (TOPIC); COMA; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONTINUOUS INFUSION; CORNEA ULCER; DEMYELINATING DISEASE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; EDEMA; ENDOCRINE OPHTHALMOPATHY; ERYTHEMA NODOSUM; EYE ALLERGY; EYE INFLAMMATION; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERVOLEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; INJECTION SITE REACTION; IRIDOCYCLITIS; KERATITIS; KIDNEY FAILURE; LEUKOCYTE; LEUKOPENIA; LIGNEOUS CONJUNCTIVITIS; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LUNG EDEMA; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOMA; MENINGISM; METASTASIS; METHEMOGLOBINEMIA; MUCOUS MEMBRANE PEMPHIGOID; MYALGIA; MYCOSIS; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; OCULAR INFLAMMATORY DISEASE; OPTIC NEURITIS; ORBIT INFLAMMATION; ORBITAL MYOSITIS; PANCYTOPENIA; PARALYSIS; PARESTHESIA; PEMPHIGUS VULGARIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA EDEMA; RETINA VASCULITIS; REVIEW; RHINOPHARYNGITIS; SCLERA DISEASE; SCLERAL MELTING; SCLERITIS; SCLERODERMA; SEBORRHEIC DERMATITIS; SEIZURE; SEPSIS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN ALLERGY; SKIN CANCER; SKIN NODULE; STEVENS JOHNSON SYNDROME; SYMPATHETIC OPHTHALMIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; TREMOR; TUBERCULOSIS; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; UVEORETINITIS; VASCULAR DISEASE; VASCULITIS; VERNAL CONJUNCTIVITIS; VIRUS REACTIVATION; VOMITING; WEGENER GRANULOMATOSIS; WEIGHT REDUCTION;

ALGORITHMS; HUMANS; IMMUNOLOGIC FACTORS; KERATITIS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PRACTICE GUIDELINES AS TOPIC; SCLERITIS; UVEITIS;

EID: 82355164291     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2011.05.003     Document Type: Review

References (359)

1. Adams A.B., Kazim M., Lehman T.J. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005, 32:1374-1375.
2. Ahmed A.R., Spigelman Z., Cavacini L.A., et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779.
3. Akpek E.K., Jabs D.A., Tessler H.H., et al. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 2002, 109:1506-1513.
4. Allison A.C., Eugui E.M. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993, 136:5-28.
5. Alonso-Ruiz A., Pijoan J.I., Ansuategui E., et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008, 9:52.
6. Alpsoy E., Durusoy C., Yilmaz E., et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467-471.
7. Andrasch R.H., Pirofsky B., Burns R.P. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978, 96:247-251.
8. Andreu J.M., Timasheff S.N. Interaction of tubulin with single ring analogues of colchicine. Biochemistry 1982, 21:534-543.
9. Anolik J., Sanz I., Looney R.J. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003, 5:350-356.
10. Antonelli A., Saracino A., Alberti B., et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol (Copenh) 1992, 126:13-23.
11. Anzaar F., Gallagher M.J., Bhat P., et al. Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea 2008, 27:884-888.
12. Appenzeller S., Hazel E. Pentoxifylline for the treatment of anterior uveitis in Behçet's disease: possible alternative for TNF blockers. Rheumatol Int 2009, 30:123-125.
13. Araujo A.A., Wells A.P., Dick A.D., et al. Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol 2000, 84:979-982.
14. Armstrong M., Needham D., Hatchell D.L., et al. Effect of pentoxifylline on the flow of polymorphonuclear leukocytes through a model capillary. Angiology 1990, 41:253-262.
15. Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999, 26:1705-1714.
16. Atmaca L.S., Batioglu F. The efficacy of cyclosporin-a in the treatment of Behçet's disease. Ophthalmic Surg 1994, 25:321-327.
17. Baker K.B., Spurrier N.J., Watkins A.S., et al. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol 2006, 90:1481-1485.
18. Balazs C., Kiss E., Vamos A., et al. [Immunomodulatory effect of pentoxifylline in Graves ophthalmopathy]. Orv Hetil 1997, 138:2869-2874.
19. Baltatzis S., Tufail F., Yu E.N., et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003, 110:1061-1065.
20. Baran D.A., Zucker M.J., Arroyo L.H., et al. A prospective, randomized trial of single versus dual drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail 2011, 4:129-137.
21. Barnett M.L., Kremer J.M., St Clair E.W., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998, 41:290-297.
22. Bath P.M., Bath F.J., Asplund K. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev 2000, 2:CD000162.
23. Baughman R.P., Bradley D.A., Lower E.E. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005, 43:7-11.
24. Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004, 21:43-48.
25. Becker M.D., Heiligenhaus A., Hudde T., et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005, 89:1254-1257.
26. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008, 1:CD006893.
27. Benezra D., Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986, 70:589-592.
28. BenEzra D., Cohen E., Rakotomalala M., et al. Treatment of endogenous uveitis with cyclosporine A. Transplant Proc 1988, 20(3 Suppl. 4):122-127.
29. Berk P.D., Goldberg J.D., Silverstein M.N., et al. Increased sincidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981, 304:441-447.
30. Bhat P., Castaneda-Cervantes R.A., Doctor P.P., et al. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 2009, 247:687-692.
31. Binder A.I., Graham E.M., Sanders M.D., et al. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987, 26:285-291.
32. Bleik J.H., Tabbara K.F. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991, 98:1679-1684.
33. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996, 61:1029-1037. [No authors listed].
34. Blumenfeld Z., Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997, 29:199-206.
35. Bodaghi B., Bui Quoc E., Wechsler B., et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005, 64:962-964.
36. Bodaghi B., Gendron G., Wechsler B., et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335-339.
37. Bom S., Zamiri P., Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 2001, 9:35-40.
38. Braun J., Brandt J., Listing J., et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233.
39. Brodsky R.A. High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 2010, 47:179-184.
40. Brubaker R., Font R.L., Shepherd E.M. Granulomatous sclerouveitis. Regression of ocular lesions with cyclophosphamide and prednisone. Arch Ophthalmol 1971, 86:517-524.
41. Brunnee T., Engelstatter R., Steinijans V.W., et al. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 1992, 5:982-985.
42. Buckley C.E., Gills J.P. Cyclophosphamide therapy of Behçet's disease. J Allergy 1969, 43:273-283.
43. Buckley C.E., Gills J.P. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969, 124:29-35.
44. Buech G., Bertelmann E., Pleyer U., et al. Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther 2007, 23:292-303.
45. Buggage R.R., Levy-Clarke G., Sen H.N., et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007, 15:63-70.
46. Bullingham R.E., Nicholls A.J., Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34:429-455.
47. Burke A., Smyth E.M., FitzGerald G.A. Analgesic-antipyretic and antiinflammatory agents; pharmacotherapy of gout. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005, McGraw-Hill Professional, New York, ed 11, pp 671-716. L.L. Brunton, J.S. Lazzo, K.L. Parker (Eds.).
48. Buttini M., Mir A., Appel K., et al. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. Br J Pharmacol 1997, 122:1483-1489.
49. Cade R., Mars D., Privette M., et al. Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. Arch Intern Med 1986, 146:737-741.
50. Calabrese L.H. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003, 21:241-248.
51. Callaway L.K., Bennett C.J. Adolescent Kawasaki disease with uveitis. Intern Med J 2002, 32:421-422.
52. Cassoux N., Goichot-Bonnat L., Karmochkine M., et al. [Efficacy of intravenous immunoglobulin in the treatment of birdshot retinochoroiditis]. J Fr Ophtalmol 2002, 25:23-30.
53. Castor C.W., Bull F.E. Review of United States data on neoplasms in rheumatoid arthritis. Am J Med 1985, 78(1A):33-38.
54. Cersosimo R.J. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm 2003, 60:1531-1548.
55. Chabner B.A., Amrein P.C., Druker B., et al. Antineoplastic agents. Goodman & Gilman's The Pharmacologic Basis of Therapeutics 2005, McGraw-Hill, New York, ed 11, pp 1315-1404. L.L. Brunton, J.S. Lazzo, K.L. Parker (Eds.).
56. Chan G.L., Canafax D.M., Johnson C.A. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987, 7:165-177.
57. Chanan-Khan A., Kipps T., Stilgenbauer S. Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse events. Clin Adv Hematol Oncol 2010, 8(Suppl):1-15.
58. Chang C.C., Chang T.C., Kao S.C., et al. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh) 1993, 129:322-327.
59. Charles S.J., Meyer P.A., Watson P.G. Diagnosis and management of systemic Wegener's granulomatosis presenting with anterior ocular inflammatory disease. Br J Ophthalmol 1991, 75:201-207.
60. Chavis P.S., Antonios S.R., Tabbara K.F. Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease. Doc Ophthalmol 1992, 80:133-142.
61. Chi Z.L., Hayasaka S., Zhang X.Y., et al. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats. Invest Ophthalmol Vis Sci 2004, 45:2497-2502.
62. Chou P.I., Chang J.S., Chen J.T., et al. The short-term effect of pentoxifylline on rabbit choroidal blood flow. J Ocul Pharmacol Ther 2000, 16:455-462.
63. Coblyn J.S., Shadick N., Helfgott S. Leflunomide-associated weight loss in rheumatoid arthritis. Arthritis Rheum 2001, 44:1048-1051.
64. Cohen S., Cannon G.W., Schiff M., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001, 44:1984-1992.
65. Connell W.R., Kamm M.A., Dickson M., et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249-1252.
66. Coupland S.E., Klebe S., Karow A.C., et al. Leflunomide therapy following penetrating keratoplasty in the rat. Graefes Arch Clin Exp Ophthalmol 1994, 232:622-627.
67. Coutinho A., Kazatchkine M.D., Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995, 7:812-818.
68. Dana M.R., Dai R., Zhu S., et al. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Invest Ophthalmol Vis Sci 1998, 39:70-77.
69. Daniel E., Thorne J.E., Newcomb C.W., et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010, 149:423-432.
70. Davatchi F., Shams H., Rezaipoor M., et al. Rituximab in intractable ocular lesions of Behçet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010, 13:246-252.
71. de Boer J.H., van Haren M.A., de Vries-Knoppert W.A., et al. Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Curr Eye Res 1992, 11(Suppl):181-186.
72. de Vries J., Baarsma G.S., Zaal M.J., et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990, 74:344-349.
73. Dees C., Arnold J.J., Forrester J.V., et al. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 1998, 116:1456-1461.
74. DeGowin R.L. A review of therapeutic and hemolytic effects of dapsone. Arch Intern Med 1967, 120:242-248.
75. Deree J., Martins J.O., Melbostad H., et al. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 2008, 63:321-328.
76. Desai S.B., Furst D.E. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006, 20:757-790.
77. Deuter C.M., Kotter I., Gunaydin I., et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 2009, 93:906-913.
78. Deuter C.M., Zierhut M., Mohle A., et al. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 1999, 62:2796-2805.
79. Dev S., McCallum R.M., Jaffe G.J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999, 106:111-118.
80. Diaz-Llopis M., Cervera M., Menezo J.L. Cyclosporin A treatment of Behçet's disease: a long-term study. Curr Eye Res 1990, 9(Suppl):17-23.
81. Diaz-Llopis M., Garcia-Delpech S., Salom D., et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008, 24:351-361.
82. Dick A.D., Azim M., Forrester J.V. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997, 81:1107-1112.
83. Dimopoulos M.A., Kastritis E., Roussou M., et al. Rituximab-based treatments in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9:59-61.
84. Dinning W.J., Perkins E.S. Immunosuppressives in uveitis. A preliminary report of experience with chlorambucil. Br J Ophthalmol 1975, 59:397-403.
85. Doycheva D., Deuter C., Stuebiger N., et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007, 91:180-184.
86. Durrani K., Papaliodis G.N., Foster C.S. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004, 111:960-965.
87. Elder M.J., Lightman S., Dart J.K. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 1995, 79:264-266.
88. Elferink J.G., Huizinga T.W., de Koster B.M. The effect of pentoxifylline on human neutrophil migration: a possible role for cyclic nucleotides. Biochem Pharmacol 1997, 54:475-480.
89. Esbenshade A.J., Ho R.H., Shintani A., et al. Dapsone-induced methemoglobinemia: A dose-related occurrence?. Cancer 2011, 117:3485-3492.
90. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 2001, 108:671-680.
91. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 2005, 50:297-350.
92. Fauci A.S., Doppman J.L., Wolff S.M. Cyclophosphamide-induced remissions in advanced polyarteritis nodosa. Am J Med 1978, 64:890-894.
93. Fauci A.S., Haynes B.F., Katz P., et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
94. Feron E.J., Rothova A., van Hagen P.M., et al. Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 1994, 343:1428.
95. Fleischmann R., Iqbal I., Nandeshwar P., et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002, 25:173-197.
96. Fleischmann R.M. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(Suppl 2):ii29-ii35.
97. Fleischmann R.M., Tesser J., Schiff M.H., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006-1012.
98. Florey H.W., Jennings M.A., et al. Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx. Lancet 1946, 1:46-49.
99. Foeldvari I., Nielsen S., Kummerle-Deschner J., et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007, 34:1146-1150.
100. Fosdick W.M., Parsons J.L., Hill D.F. Long-term cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968, 11:151-161.
101. Foster C.S. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986, 84:527-663.
102. Foster C.S., Chang P.Y., Ahmed A.R. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010, 117:861-869.
103. Foster C.S., Maza M.S.D.L. The Sclera 1993, Springer Verlag, New York.
104. Foster C.S., Raizman M.B. Therapeutic response to systemic immunosuppressive chemotherapy agents in patients with Behçet's syndrome effecting the eyes. Behçet's Disease: Basic and Clinical Aspects 1991, 581-588. Marcel Dekker, New York. J. O'Duffy (Ed.).
105. Foster C.S., Tufail F., Waheed N.K., et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437-440.
106. Foster C.S., Vitale A.T. Immunosuppressive chemotherapy. Diagnosis and Treatment of Uveitis 2002, WB Saunders, Philadelphia, PA, ed 1, pp 177-214. C.S. Foster, A.T. Vitale (Eds.).
107. Foster C.S., Wilson L.A., Ekins M.B. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982, 89:340-353.
108. Fox R.I., Herrmann M.L., Frangou C.G., et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999, 93:198-208.
109. Franks W.A., Limb G.A., Stanford M.R., et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992, 11(Suppl):187-191.
110. Galindo-Rodriguez G., Avina-Zubieta J.A., Pizarro S., et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 1999, 106:65-69.
111. Gallagher M., Quinones K., Cervantes-Castaneda R.A., et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91:1341-1344.
112. Galor A., Jabs D.A., Leder H.A., et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008, 115:1826-1832.
113. Galor A., Perez V.L., Hammel J.P., et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113:2317-2323.
114. Gangaputra S., Newcomb C.W., Liesegang T.L., et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009, 116:2188-2198.
115. Gion N., Stavrou P., Foster C.S. Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol 2000, 129:764-768.
116. Godfrey W.A., Epstein W.V., O'Connor G.R., et al. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol 1974, 78:415-428.
117. Golay J., Manganini M., Facchinetti V., et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003, 88:1002-1012.
118. Goldbach-Mansky R. Blocking interleukin-1 in rheumatic diseases. Ann NY Acad Sci 2009, 1182:111-123.
119. Goldstein D.A., Fontanilla F.A., Kaul S., et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002, 109:370-377.
120. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
121. Gonzalez-Delgado M., Gonzalez C., Blazquez J.I., et al. [Intravenous immunoglobulin therapy in Vogt-Koyanagi-Harada syndrome]. Neurologia 2004, 19:401-403.
122. Gordon D., McLean J. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy in ophthalmologic conditions. J Am Med Assoc 1950, 142:1271-1276.
123. Gottardo N.G., Baker D.L., Willis F.R. Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab. Pediatr Hematol Oncol 2003, 20:557-561.
124. Greenwood A.J., Stanford M.R., Graham E.M. The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 1998, 12(Pt 5):783-788.
125. Greiner K., Varikkara M., Santiago C., et al. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis]. Ophthalmologe 2002, 99:691-694.
126. Gueudry J., Wechsler B., Terrada C., et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008, 146:837-844.
127. Hakin K.N., Ham J., Lightman S.L. Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Br J Ophthalmol 1991, 75:340-341.
128. Harbinson P.L., MacLeod D., Hawksworth R., et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997, 10:1008-1014.
129. Hauselmann H.J., Caravatti M., Seifert B., et al. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Br J Rheumatol 1998, 37:1110-1117.
130. Hayden F.G. Antiviral agents (nonretroviral). Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005, McGraw-Hill Professional, New York, ed 11, pp 1243-72. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
131. Hemady R.K., Baer J.C., Foster C.S. Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992, 32:241-252.
132. Hoang-Xaun T., Foster C.S., Rice B.A. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology 1990, 97:892-898.
133. Hogan A.C., McAvoy C.E., Dick A.D., et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007, 114:1000-1006.
134. Holland E.J., Chan C.C., Kuwabara T., et al. Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol 1989, 107:160-166.
135. Holz F.G., Krastel H., Breitbart A., et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992, 1:142-144.
136. Hooper P.L., Kaplan H.J. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology 1991, 98:944-951. discussion 51-2.
137. Iaccheri B., Androudi S., Bocci E.B., et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010, 18:223-225.
138. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000, 130:492-513.
139. Jie Y., Zhang W.H., Pan Z.Q., et al. Interleukin-1 receptor antagonist eye drops promoting high-risk corneal allografts survival in rats. Chin Med J (Engl) 2004, 117:711-716.
140. Jung S., Zielasek J., Kollner G., et al. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996, 68:1-11.
141. Kacmaz R.O., Kempen J.H., Newcomb C., et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010, 117:576-584.
142. Kahn P., Weiss M., Imundo L.F., et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006, 113:860-864.
143. Kambayashi T., Jacob C.O., Zhou D., et al. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995, 155:4909-4916.
144. Kaplan-Messas A., Barkana Y., Avni I., et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 2003, 11:131-139.
145. Kaymakcalan Z., Sakorafas P., Bose S., et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009, 131:308-316.
146. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
147. Kazokoglu H., Saatci O., Cuhadaroglu H., Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Behçet's disease. Ann Ophthalmol 1991, 23:148-151.
148. Keane-Myers A.M., Miyazaki D., Liu G., et al. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 1999, 40:3041-3046.
149. Kempen J.H., Daniel E., Dunn J.P., et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009, 339:2480.
150. Kempen J.H., Gangaputra S., Daniel E., et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008, 146:802-812.
151. Khalilzadeh O., Anvari M., Esteghamati A., et al. Graves' ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Experiment Ophthalmol 2009, 37:614-619.
152. Kilmartin D.J., Forrester J.V., Dick A.D. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998, 82:737-742.
153. Kirtschig G., Murrell D., Wojnarowska F., et al. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003, 1:CD004056.
154. Klemm P., Harris H.J., Perretti M. Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone. Eur J Pharmacol 1995, 281:69-74.
155. Kotter I., Gunaydin I., Zierhut M., et al. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 2004, 33:320-335.
156. Kotter I., Vonthein R., Zierhut M., et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004, 33:311-319.
157. Kremer J.M., Alarcon G.S., Lightfoot R.W., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37:316-328.
158. Krensky A.M., Vincenti F., Bennett W.W. Immunosuppressants, tolerogens and immunostimulants. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005, 1405-1432. The McGraw-Hill Companies, New York. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
159. Kruit P.J., van Balen A.T., Stilma J.S. Cyclosporin A treatment in two cases of corneal peripheral melting syndrome. Doc Ophthalmol 1985, 59:33-39.
160. Kymionis G.D., Goldman D., Ide T., et al. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008, 27:228-229.
161. Land S.C., Tee A.R. Hypoxia-inducible factor 1-alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007, 282:20534-20543.
162. Lau C.H., Comer M., Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003, 31:487-491.
163. Lazar M., Weiner M.J., Leopold I.H. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969, 67:383-387.
164. Le Hoang P., Girard B., Deray G., et al. Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 1988, 20(3 Suppl. 4):128-130.
165. Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 11:1135-46.
166. LeHoang P., Cassoux N., George F., et al. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul Immunol Inflamm 2000, 8:49-57.
167. Lerner H.J. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 1978, 62:1135-1138.
168. Letko E., Miserocchi E., Daoud Y.J., et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004, 111:303-310.
169. Letko E., Zafirakis P., Baltatzis S., et al. Relapsing polychondritis: a clinical review. Semin Arthritis Rheum 2002, 31:384-395.
170. Leznoff A., Shea M., Binkley K.E., et al. Cyclosporine in the treatment of nonmicrobial inflammatory ophthalmic disease. Can J Ophthalmol 1992, 27:302-306.
171. Lim L., Suhler E.B., Smith J.R. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006, 34:365-374.
172. Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248-3252.
173. Lim W.K., Fujimoto C., Ursea R., et al. Suppression of immune-mediated ocular inflammation in mice by interleukin 1 receptor antagonist administration. Arch Ophthalmol 2005, 123:957-963.
174. Lin J., Ziring D., Desai S., et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30.
175. Louie S.G., Park B., Yoon H. Biological response modifiers in the management of rheumatoid arthritis. Am J Health Syst Pharm 2003, 60:346-355.
176. MacDonald A., Scarola J., Burke J.T., et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000, 22(Suppl B):101-121.
177. Mackensen F., Max R., Becker M.D. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009, 3:559-566.
178. Magro F., Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010, 24(Suppl 1):3-14.
179. Mamo J.G. Treatment of Behçet disease with chlorambucil. A follow-up report. Arch Ophthalmol 1976, 94:580-583.
180. Martenet A. Immunosuppressive therapy of uveitis: mid- and long-term follow up after classical cytostatic treatment. Ocular Immunology Today 1990, 443-446. Excerpta Medica, New York. M. Usui, S. Ohno, K. Aoki (Eds.).
181. Martin-Suarez I., D'Cruz D., Mansoor M., et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481-487.
182. Martin D.F., DeBarge L.R., Nussenblatt R.B., et al. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995, 154:922-927.
183. Masuda K., Nakajima A., Urayama A., et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989, 1:1093-1096.
184. Mathews J.D., Crawford B.A., Bignell J.L., Mackay I.R. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol 1969, 53:327-330.
185. Matsumura N., Mizushima Y. Leucocyte movement and colchicine treatment in Behçet's disease. Lancet 1975, 2:813.
186. Matsuyama M., Suzuki T., Tsuboi H., et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007, 46:771-774.
187. Mayer A.D., Dmitrewski J., Squifflet J.P., et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997, 64:436-443.
188. McCarthy J.M., Dubord P.J., Chalmers A., et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol 1992, 19:1358-1361.
189. McCluskey P., Chang J.H., Singh R., et al. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004, 111:796-801.
190. Meijer J.M., Meiners P.M., Vissink A., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
191. Miller K., Huber C., Niederwieser D., et al. Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation 1988, 45:651-653.
192. Miserocchi E., Baltatzis S., Ekong A., et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 2002, 109:137-142.
193. Mita M.M., Mita A., Rowinsky E.K. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003, 2(4 Suppl. 1):S169-S177.
194. Mizushima Y. Behçet's disease. Curr Opin Rheumatol 1991, 3:32-35.
195. Mizushima Y., Matsumura N., Mori M., et al. Colchicine in Behçet's disease. Lancet 1977, 2:1037.
196. Mochizuki M., Masuda K., Sakane T., et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993, 115:763-769.
197. Molnar-Kimber K.L., Yonno L., Heaslip R.J., Weichman B.M. Differential regulation of TNF-alpha and IL-1beta production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Mediators Inflamm 1992, 1:411-417.
198. Mondino B.J., Brown S.I. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983, 96:453-459.
199. Moore C.E. Sympathetic ophthalmitis treated with azathioprine. Br J Ophthalmol 1968, 52:688-690.
200. Moro J.A., Almenar L., Martinez-Dolz L., et al. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008, 40:3034-3036.
201. Mudun B.A., Ergen A., Ipcioglu S.U., et al. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm 2001, 9:219-229.
202. Muftuoglu A.U., Pazarli H., Yurdakul S., et al. Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol 1987, 71:387-390.
203. Murphy C.C., Greiner K., Plskova J., et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005, 123:634-641.
204. Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007, 21:824-825.
205. Naik P.M., Lyon G.M., Ramirez A., et al. Dapsone-induced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant 2008, 27:1198-1202.
206. Neumann R., Tauber J., Foster C.S. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991, 98:858-862.
207. Newell D.R., Calvert A.H., Harrap K.R., et al. Studies on the pharmacokinetics of chlorambucil and prednimustine in man. Br J Clin Pharmacol 1983, 15:253-258.
208. Newell F.W., Krill A.E. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967, 87:499-511.
209. Niccoli L., Nannini C., Benucci M., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46:1161-1164.
210. Nissen C., Bendtzen K., Tvede N., et al. The treatment of presumed non-infective uveitis with cyclosporin A. Acta Ophthalmol 1985, 173(Suppl):72-73.
211. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1985, 1:369-382.
212. Nussenblatt R.B., Palestine A.G., Chan C.C., et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991, 112:138-146.
213. O'Duffy J.D., Robertson D.M., Goldstein N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 1984, 76:75-84.
214. Ohta K., Wiggert B., Yamagami S., et al. Analysis of immunomodulatory activities of aqueous humor from eyes of mice with experimental autoimmune uveitis. J Immunol 2000, 164:1185-1192.
215. Ohta K., Yamagami S., Taylor A.W., et al. IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000, 41:2591-2599.
216. Okada A.A. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005, 13:335-351.
217. Oldfield V., Dhillon S., Plosker G.L. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009, 69:609-632.
218. Onal S., Foster C.S., Ahmed A.R. Efficacy of intravenous immunoglobulin treatment in refractory uveitis. Ocul Immunol Inflamm 2006, 14:367-374.
219. Ozdal P.C., Ortac S., Taskintuna I., et al. Long-term therapy with low dose cyclosporin A in ocular Behçet's disease. Doc Ophthalmol 2002, 105:301-312.
220. Ozyazgan Y., Yurdakul S., Yazici H., et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 1992, 76:241-243.
221. Pacheco P.A., Taylor S.R., Cuchacovich M.T., et al. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 2008, 16:161-165.
222. Palestine A.G., Nussenblatt R.B., Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc 1988, 20(3 Suppl. 4):131-135.
223. Papaliodis G.N., Chu D., Foster C.S. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786-789.
224. Pasadhika S., Kempen J.H., Newcomb C.W., et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009, 148:500-509.
225. Pascalis L., Pia G., Aresu G., et al. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun 1993, 6:467-480.
226. Patapanian H., Graham S., Sambrook P.N., et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 1988, 27:44-47.
227. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery 1978, 83:492-502.
228. Perez V.L., Papaliodis G.N., Chu D., et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts Eye & Ear experience and review of previous studies. Ocul Immunol Inflamm 2004, 12:193-201.
229. Peters D.H., Fitton A., Plosker G.L., et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993, 46:746-794.
230. Pham S.M., Kormos R.L., Hattler B.G., et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996, 111:764-772.
231. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995, 345:1321-1325. [No authors listed].
232. Plotkin J.S., Buell J.F., Njoku M.J., et al. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: a two-case report and review. Liver Transpl Surg 1997, 3:149-152.
233. Plskova J., Greiner K., Forrester J.V. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144:55-61.
234. Ponticelli C., Scolari M.P. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review. Transplant Proc 2010, 42:2205-2208.
235. Priori R., Paroli M.P., Luan F.L., et al. Cyclosporin A in the treatment of relapsing polychondritis with severe recurrent eye involvement. Br J Rheumatol 1993, 32:352.
236. Puavilai S., Chutha S., Polnikorn N., et al. Incidence of anemia in leprosy patients treated with dapsone. J Med Assoc Thai 1984, 67:404-407.
237. Pujari S.S., Kempen J.H., Newcomb C.W., et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010, 117:356-365.
238. Purvin V., Ranson N., Kawasaki A. Idiopathic recurrent neuroretinitis: effects of long-term immunosuppression. Arch Ophthalmol 2003, 121:65-67.
239. Raizman M.B., Fay A.M., Weiss J.S. Dapsone-induced neutropenia in patients treated for ocular cicatricial pemphigoid. Ophthalmology 1994, 101:1805-1807.
240. Rajaraman R.T., Kimura Y., Li S., et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006, 113:308-314.
241. Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 2003, 48:2079-2080.
242. Reiff A., Takei S., Sadeghi S., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415.
243. Resnikoff S., Pascolini D., Etya'ale D., et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004, 82:844-851.
244. Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 29:559-61.
245. Reyes J., Tzakis A., Green M., et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc 1991, 23:3044-3046.
246. Riksen N.P., Smits P., Rongen G.A. The cardiovascular effects of methylxanthines. Handb Exp Pharmacol 2011, 200:413-437.
247. Roberge F.G., Xu D., Chan C.C., et al. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res 1993, 12:197-203.
248. Robert N., Wong G.W., Wright J.M. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010, 1:CD007893.
249. Robertson S.M., Lang L.S. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 1994, 42:167-172.
250. Roda Perez E. [Case of uveitis of unknown etiology treated with nitrogen mustards. ]. Rev Clin Esp 1951, 41:265-267.
251. Rodriguez M., Lennon V.A. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990, 27:12-17.
252. Romano M., Sironi M., Toniatti C., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6:315-325.
253. Rosenbaum J.T. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994, 21:123-125.
254. Rosenbaum J.T., Boney R.S. Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol 1992, 110:547-549.
255. Rosenbaum J.T., George R.K., Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999, 127:545-549.
256. Rosenbaum J.T., Simpson J., Neuwelt C.M. Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol 1997, 81:130-132.
257. Ross S.E., Williams R.O., Mason L.J., et al. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997, 159:6253-6259.
258. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996, 80:332-336.
259. Rubbert-Roth A., Tak P.P., Zerbini C., et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010, 49:1683-1693.
260. Rudwaleit M., Claudepierre P., Wordsworth P., et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801-808.
261. Rudwaleit M., Rodevand E., Holck P., et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009, 68:696-701.
262. Ruhlmann A., Nordheim A. Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation. Immunobiology 1997, 198:192-206.
263. Sajjadi H., Soheilian M., Ahmadieh H., et al. Low dose cyclosporin-a therapy in Behçet's disease. J Ocul Pharmacol 1994, 10:553-560.
264. Sami N., Letko E., Androudi S., et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004, 111:1380-1382.
265. Samson C.M., Waheed N., Baltatzis S., Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001, 108:1134-1139.
266. Sansone F., Boffini M., Comoglio C., et al. Results with cyclosporine monotherapy in long-term cardiac transplant recipients. Transplant Proc 2010, 42:1291-1293.
267. Saougou I., Markatseli T.E., Papagoras C., et al. sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011, 40:398-406.
268. Saurenmann R.K., Levin A.V., Rose J.B., et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45:982-989.
269. Saw V.P., Dart J.K., Rauz S., et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008, 115:253-261.
270. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
271. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
272. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004, 15:280-294.
273. Schmeling H., Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005, 44:1008-1011.
274. Schmetterer L., Kemmler D., Breiteneder H., et al. A randomized, placebo-controlled, double-blind crossover study of the effect of pentoxifylline on ocular fundus pulsations. Am J Ophthalmol 1996, 121:169-176.
275. Schreiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136-142.
276. Secchi A.G., De Rosa C., Pivetti-Pezzi P., et al. Open noncontrolled multicenter long-term trial with ciclosporin in endogenous non-infectious uveitis. Ophthalmologica 1991, 202:217-224.
277. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
278. Seider N., Beiran I., Scharf J., et al. Intravenous immunoglobulin therapy for resistant ocular Behçet's disease. Br J Ophthalmol 2001, 85:1287-1288.
279. Sen H.N., Levy-Clarke G., Faia L.J., et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009, 148:696-703.
280. Sen H.N., Suhler E.B., Al-Khatib S.Q., et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology 2003, 110:1750-1755.
281. Seppel T., Schlaghecke R., Becker A., et al. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy. Clin Exp Rheumatol 1996, 14(Suppl 15):S109-S114.
282. Sethi G., Sung B., Kunnumakkara A.B., et al. Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 2009, 647:37-51.
283. Sfikakis P.P. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002, 61(Suppl 2):ii51-ii53.
284. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004, 140:404-406.
285. Shah S.S., Lowder C.Y., Schmitt M.A., et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992, 99:1419-1423.
286. Shambal S., Lindner A., Zierz S. Successful treatment of orbital myositis with intravenous immunoglobulins. Muscle Nerve 1998, 21:1359-1360.
287. Shanmuganathan V.A., Casely E.M., Raj D., et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol 2005, 89:666-669.
288. Shenoi S., Wallace C.A. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010, 12:367-377.
289. Sieper J., Kary S., Sorensen H., et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996, 39:41-51.
290. Siepmann K., Huber M., Stubiger N., et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006, 244:788-794.
291. Silkiss R.Z., Reier A., Coleman M., et al. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 2010, 26:310-314.
292. Simonini G., Taddio A., Cattalini M., et al. Prevention of flare recurrences in childhood refractory chronic uveitis: An open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011, 63:612-618.
293. Singh G., Fries J.F., Spitz P., et al. Toxic effects of azathioprine in rheumatoid arthritis. A national postmarketing perspective. Arthritis Rheum 1989, 32:837-843.
294. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2:CD008794.
295. Smith J.R., Levinson R.D., Holland G.N., et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001, 45:252-257.
296. Smith J.R., Rosenbaum J.T. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001, 85:1220-1224.
297. Sobrin L., Christen W., Foster C.S. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 2008, 115:1416-1421.
298. Sobrin L., Huang J.J., Christen W., et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008, 126:186-191.
299. Sobrin L., Kim E.C., Christen W., et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895-900.
300. Spatz S., Rudnicka A., McDonald C.J. Mycophenolic acid in psoriasis. Br J Dermatol 1978, 98:429-435.
301. Staines N.A., Hardingham T., Smith M., et al. Collagen-induced arthritis in the rat: modification of immune and arthritic responses by free collagen and immune anti-collagen antiserum. Immunology 1981, 44:737-744.
302. Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med. 122:176-84.
303. Suhler E.B., Smith J.R., Giles T.R., et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009, 127:819-822.
304. Suhler E.B., Smith J.R., Wertheim M.S., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123:903-912.
305. Sullu Y., Oge I., Erkan D., et al. Cyclosporin-a therapy in severe uveitis of Behçet's disease. Acta Ophthalmol Scand 1998, 76:96-99.
306. Sunakawa M. High-dose intravenous gammaglobulin therapy for uveitis. Metab Pediatr Syst Ophthalmol 1989, 12:93-95.
307. Suttorp-Schulten M.S., Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996, 80:844-848.
308. Tabbara K.F. Chlorambucil in Behçet's disease. A reappraisal. Ophthalmology 1983, 90:906-908.
309. Tauber J., Sainz de la Maza M., Foster C.S. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991, 10:185-195.
310. Taylor S.R., Salama A.D., Joshi L., et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009, 60:1540-1547.
311. Teixeira M.M., Rossi A.G., Williams T.J., et al. Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea pig. Br J Pharmacol 1994, 112:332-340.
312. Teoh S.C., Sharma S., Hogan A., et al. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 2007, 91:263-264.
313. Terkeltaub R.A. Colchicine update: 2008. Semin Arthritis Rheum 2009, 38:411-419.
314. Thompson D.J., Barron K.S., Whitcup S.M., et al. The safety and efficacy of chicken type II collagen on uveitis associated with juvenile rheumatoid arthritis. Ocul Immunol Inflamm 2002, 10:83-91.
315. Towler H.M., Cliffe A.M., Whiting P.H., et al. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye (Lond) 1989, 3(Pt 3):282-287.
316. Towler H.M., Whiting P.H., Forrester J.V. Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye (Lond) 1990, 4(Pt 3):514-520.
317. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993, 261:1727-1730.
318. Treon S.P., Anderson K.C. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000, 27(6 Suppl. 12):79-85.
319. Tsai M.L., Horng C.T., Chen S.L., et al. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis 2009, 15:1542-1552.
320. Tugal-Tutkun I., Guney-Tefekli E., Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692-1695.
321. Tutuncu Z., Kavanaugh A. Anticytokine therapies. Kelley's Textbook of Rheumatology, Vol. 1 2009, Saunders/Elsevier, Philadelphia, ed 8, pp 929-46. G.S. Firestein, R.C. Budd (Eds.).
322. Tyden G., Kumlien G., Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003, 76:730-731.
323. Tynjala P., Kotaniemi K., Lindahl P., et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008, 47:339-344.
324. Urcelay M.L., McQueen A., Douglas W.S. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 1997, 137:477-478.
325. van Engelen B.G., Hommes O.R., Pinckers A., et al. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992, 32:834-835.
326. Vedot E. Epidemiology of intermediate uveitis. A prospective study in Savoy. Dev Ophthalmol 1992, 23:33-34.
327. Venkiteshwaran A. Tocilizumab. MAbs. 2009;1:432-8.
328. Venning V.A., Millard P.R., Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989, 120:83-92.
329. Virtanen H.M., Reitamo S., Kari M., et al. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006, 84:693-695.
330. Vitale A.T., Rodriguez A., Foster C.S. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology 1994, 101:822-831.
331. Wakefield D., McCluskey P. Cyclosporin therapy for severe scleritis. Br J Ophthalmol 1989, 73:743-746.
332. Wakefield D., McCluskey P. Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol 1991, 7:221-226.
333. Walker A.M., Funch D., Dreyer N.A., et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993, 36:329-335.
334. Walton R.C., Nussenblatt R.B., Whitcup S.M. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 1998, 105:2028-2034.
335. Ward A., Clissold S.P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987, 34:50-97.
336. Webster A.C., Ruster L.P., McGee R., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010, 1:CD003897.
337. Weinblatt M.E. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985, 12(Suppl):35-39.
338. Weiss A.H., Wallace C.A., Sherry D.D. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133:266-268.
339. Whitcup S.M., Salvo E.C., Nussenblatt R.B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 1994, 118:39-45.
340. Wiederrecht G., Lam E., Hung S., et al. The mechanism of action of FK506 and cyclosporin A. Ann NY Acad Sci 1993, 696:9-19.
341. Wiens A., Correr C.J., Venson R., et al. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. Rheumatol Int 2010, 30:1063-1070.
342. William A., Petri J. Chemotherapy of tuberculosis, mycobacterium avium complex disease, and leprosy. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2005, 1203-1224. The McGraw-Hill Companies, New York. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
343. Wong V. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 1965, 69:14.
344. Wong V.G. Methotrexate treatment of uveal disease. Am J Med Sci 1966, 251:239-241.
345. Wooley P.H., Dutcher J., Widmer M.B., et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 151:6602-6607.
346. Wozel G., Barth J. Current aspects of modes of action of dapsone. Int J Dermatol 1988, 27:547-552.
347. Wynn D., Kaufman M., Montalban X., et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010, 9:381-390.
348. Xu H., Strassmann G., Chan C.C., et al. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Invest Ophthalmol Vis Sci 1999, 40:942-950.
349. Yamada J., Zhu S.N., Streilein J.W., et al. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci 2000, 41:4203-4208.
350. Yang H., Wang J., Du J., et al. Structural basis of immunosuppression by the therapeutic antibody daclizumab. Cell Res 2010, 20:1361-1371.
351. Yasui K., Ohta K., Kobayashi M., et al. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 1996, 124:891-893.
352. Yazici H., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990, 322:281-285.
353. Yeh S., Wroblewski K., Buggage R., et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008, 31:91-97.
354. Yokota S., Imagawa T., Mori M., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
355. Youngster I., Arcavi L., Schechmaster R., et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf 2010, 33:713-726.
356. Zhu S.N., Dana M.R. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci 1999, 40:1427-1434.
357. Zierhut M., Stubiger N., Siepmann K., et al. MMF and eye disease. Lupus 2005, 14(Suppl 1):s50-s54.
358. Zivanovic D, Medenica L, Tanasilovic S, et al. Dexamethasone-cyclophosphamide pulse therapy in pemphigus: a review of 72 cases. Am J Clin Dermatol. 11:123-9.
359. Zouboulis C.C., Orfanos C.E. Treatment of Adamantiades-Behçet disease with systemic interferon alfa. Arch Dermatol 1998, 134:1010-1016.